The stock has a 36-month beta value of 1.63. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MBIO is 7.65M, and at present, short sellers hold a 2.33% of that float. On April 16, 2024, the average trading volume of MBIO was 177.42K shares.
MBIO) stock’s latest price update
Mustang Bio Inc (NASDAQ: MBIO) has experienced a decline in its stock price by -26.18 compared to its previous closing price of 0.51. However, the company has seen a fall of -46.31% in its stock price over the last five trading days. GlobeNewsWire reported 2023-09-07 that WORCESTER, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in two upcoming investor conferences in New York City.
MBIO’s Market Performance
MBIO’s stock has fallen by -46.31% in the past week, with a monthly drop of -62.30% and a quarterly drop of -74.32%. The volatility ratio for the week is 24.01% while the volatility levels for the last 30 days are 17.08% for Mustang Bio Inc The simple moving average for the past 20 days is -57.47% for MBIO’s stock, with a -83.25% simple moving average for the past 200 days.
Analysts’ Opinion of MBIO
Many brokerage firms have already submitted their reports for MBIO stocks, with BTIG Research repeating the rating for MBIO by listing it as a “Buy.” The predicted price for MBIO in the upcoming period, according to BTIG Research is $11 based on the research report published on May 18, 2021 of the previous year 2021.
B. Riley FBR, on the other hand, stated in their research note that they expect to see MBIO reach a price target of $9. The rating they have provided for MBIO stocks is “Buy” according to the report published on October 02nd, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to MBIO, setting the target price at $7 in the report published on November 20th of the previous year.
MBIO Trading at -66.56% from the 50-Day Moving Average
After a stumble in the market that brought MBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.41% of loss for the given period.
Volatility was left at 17.08%, however, over the last 30 days, the volatility rate increased by 24.01%, as shares sank -60.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.02% lower at present.
During the last 5 trading sessions, MBIO fell by -46.31%, which changed the moving average for the period of 200-days by -93.65% in comparison to the 20-day moving average, which settled at $0.8529. In addition, Mustang Bio Inc saw -72.22% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBIO
The total capital return value is set at -20.82. Equity return is now at value -222.44, with -93.68 for asset returns.
Based on Mustang Bio Inc (MBIO), the company’s capital structure generated 0.95 points at debt to capital in total, while cash flow to debt ratio is standing at -19.81. The debt to equity ratio resting at 20.31. The interest coverage ratio of the stock is -37.81.
Currently, EBITDA for the company is -48.5 million with net debt to EBITDA at 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.74.
Conclusion
To sum up, Mustang Bio Inc (MBIO) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
